The global hepatitis B treatment market is expected to register an approximate CAGR of 5.3% during the forecast period, i.e., from 2018 to 2024.
Hepatitis is a viral infection caused by Hepatitis A, B or C virus. The infection results to cause liver infection or inflammation and many times leading to liver damage.
Hepatitis B virus spreads through coming in contact with infected blood, drinking contaminated water, and using infected needles or syringes. The person suffering from Hepatitis B faces various symptoms such as poor appetite, weakness, jaundice, dark-colored urine, itching on skin, swelling on legs, weight loss, drowsiness and many more. According to the World Health Organization 2018 fact sheet, it was estimated that 257 million people across the world have lived with hepatitis B infection and also mentioned that around 887,000 number of people died from hepatitis B in 2015. Thus, the increasing prevalence of Hepatitis B across the world boosts market growth.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7817
However, the factors such as side effects associated with treatment and medications hinder the market growth.
Segmentation
The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.
Regional Analysis
The Americas dominates the global market for hepatitis B treatment. Factors such as the presence of a large number of healthcare companies, increasing geriatric population and high healthcare expenditure among the population within the Americas drives the market. The National Vaccine Information Center reported 3,370 cases of hepatitis B were reported in the US in 2015.
Following similar trends, Europe stood second in the global hepatitis B treatment market. The increased prevalence of viral diseases and growing healthcare expenditure in this region boost market growth. Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth. Asia Pacific was the fastest growing region for the global hepatitis B treatment market in 2017. This can be attributed due to the increasing incidences of HIV infection and rising demand for the treatment of viral infection among the population boosts market growth.
On the other hand, the Middle East and Africa holds the least share in the global hepatitis B treatment market. The poor economies within the African region and lack of awareness about the treatment methods hinder the market growth.
Key Players
Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/sample_request/7817
No comments:
Post a Comment